Mostrar el registro sencillo del ítem
dc.contributor.author | Krstić, Luna | |
dc.contributor.author | Jarho, Pekka | |
dc.contributor.author | Ruponen, Marika | |
dc.contributor.author | Urtti, Arto | |
dc.contributor.author | González García, María Jesús | |
dc.contributor.author | Diebold Luque, María Yolanda | |
dc.date.accessioned | 2024-01-22T13:36:07Z | |
dc.date.available | 2024-01-22T13:36:07Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | International Journal of Pharmaceutics, 2022, vol. 624, 122028 | es |
dc.identifier.issn | 0378-5173 | es |
dc.identifier.uri | https://uvadoc.uva.es/handle/10324/64818 | |
dc.description | Producción Científica | es |
dc.description.abstract | The number of patients affected by Dry Eye Disease (DED) had notably increased worldwide, addressing the need of novel therapeutic approaches. Polyphenols, quercetin (QUE) and resveratrol (RSV) show necessary antioxidant and anti-inflammatory properties to manage DED, but their application as topical eyedrops is restricted by low aqueous solubility and low chemical stability. Cyclodextrins (CD) are widely used to improve physicochemical characteristics of drugs. Consequently, the aim of this study was to make a comparison between binary complexes with quercetin, resveratrol and cyclodextrins and tertiary complexes adding hyaluronic acid (HA). Both complexes were able to enhance solubility and stability of QUE and RSV. AFM imaging and DLS measurements disclose the formation of spherical nanoaggregates within tertiary complexes of both QUE and RSV with mean diameters of 103 and 82 nm. Neither complex demonstrated cytotoxic effect in in vitro studies in corneal (HCE) and conjunctival (IM-ConjEpi) cell lines. In HCE cells, complexes containing QUE or RSV at their highest concentrations were able to scavenge more than 95 % of the ROS that were produced intracellularly (p < 0.005). Similar response was observed with IM-ConjEpi cells. The antioxidant effect was maintained in the complexes with HA. This confirmed their potential as viable topical treatment for DED | es |
dc.format.mimetype | application/pdf | es |
dc.language.iso | eng | es |
dc.publisher | Elsevier | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Oftalmología | es |
dc.subject | quercetin | es |
dc.subject | resveratrol | es |
dc.subject.classification | Dry eye disease | es |
dc.subject.classification | Cyclodextrins | es |
dc.subject.classification | Quercetin | es |
dc.subject.classification | Enfermedad del ojo seco | es |
dc.subject.classification | Ciclodextrinas | es |
dc.subject.classification | Quercetina | es |
dc.title | Improved ocular delivery of quercetin and resveratrol: A comparative study between binary and ternary cyclodextrin complexes | es |
dc.type | info:eu-repo/semantics/article | es |
dc.rights.holder | © 2022 The Authors | es |
dc.identifier.doi | 10.1016/j.ijpharm.2022.122028 | es |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S037851732200583X?via%3Dihub | es |
dc.identifier.publicationfirstpage | 122028 | es |
dc.identifier.publicationtitle | International Journal of Pharmaceutics | es |
dc.identifier.publicationvolume | 624 | es |
dc.peerreviewed | SI | es |
dc.description.project | H2020 Marie Skłodowska-Curie Actions (grant number 765608) | es |
dc.description.project | Ministerio de Ciencia e Innovación y Ministerio de Universidades - FEDER (RTI2018-094071-B-C21) | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es |
dc.subject.unesco | 3201.09 Oftalmología | es |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
La licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional